

Felzartamab for IgA Nephropathy: Final Results of the IGNAZ Study (NCT05065970)

Methods



Randomized



Double-blind



Felzartamab vs PBO

6 months treatment (9-dose arm) + 18 month off-treatment follow-up



Biopsy
confirmed IgAN

Cohort



$\text{eGFR} \geq 30$
 ml/min/1.73m^2

Mean eGFR 74.6



Proteinuria ≥ 1
 g/24 hour

Mean UPCR 1.7 g/g



RASi maximum
tolerated dose


Outcomes on and off treatment



Attenuated decline in kidney
function



Reduces proteinuria



IgA durable reductions



Common AE: IRR

PBO: placebo; UPCR: urine protein creatinine ratio; RASi: renin angiotensin system inhibitors; AE: adverse effect; IRR: infusion-related reaction (IRR)